Anne C Goodeve

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5352313/publications.pdf

Version: 2024-02-01

131 papers	5,769 citations	81839 39 h-index	79644 73 g-index
135 all docs	135 docs citations	135 times ranked	4214 citing authors

#	Article	IF	Citations
1	Phenotype and genotype of a cohort of families historically diagnosed with type 1 von Willebrand disease in the European study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebrand Disease (MCMDM-1VWD). Blood, 2007, 109, 112-121.	0.6	364
2	Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia. British Journal of Haematology, 2001, 113, 983-988.	1.2	339
3	The diagnosis and management of von <scp>W</scp>illebrand disease: a <scp>U</scp>nited <scp>K</scp>ingdom <scp>H</scp>aemophilia <scp>C</scp>entre <scp>D</scp>octors <scp>O</scp>rganization guideline approved by the <scp>B</scp>ritish <scp>C</scp>ommittee for <scp>S</scp>tandards in <scp>H</scp>aematology. British Journal of Haematology, 2014, 167, 453-465.	1.2	297
4	Incidence and prognosis of c-KIT and FLT3 mutations in core binding factor (CBF) acute myeloid leukaemias. British Journal of Haematology, 2003, 121, 775-777.	1.2	283
5	FLT3 internal tandem duplication mutations in adult acute myeloid leukaemia define a high-risk group. British Journal of Haematology, 2000, 111, 190-195.	1.2	257
6	c-kit proto-oncogene exon 8 in-frame deletion plus insertion mutations in acute myeloid leukaemia. British Journal of Haematology, 1999, 105, 894-900.	1.2	229
7	Response to desmopressin is influenced by the genotype and phenotype in type 1 von Willebrand disease (VWD): results from the European Study MCMDM-1VWD. Blood, 2008, 111, 3531-3539.	0.6	187
8	Principles of care for the diagnosis and treatment of von Willebrand disease. Haematologica, 2013, 98, 667-674.	1.7	175
9	HLA Class II Profile: A Weak Determinant of Factor VIII Inhibitor Development in Severe Haemophilia A. Thrombosis and Haemostasis, 1997, 77, 234-237.	1.8	163
10	A high-throughput sequencing test for diagnosing inherited bleeding, thrombotic, and platelet disorders. Blood, 2016, 127, 2791-2803.	0.6	157
11	Identification of type 1 von Willebrand disease patients with reduced von Willebrand factor survival by assay of the VWF propeptide in the European study: Molecular and Clinical Markers for the Diagnosis and Management of Type 1 VWD (MCMDM-1VWD). Blood, 2008, 111, 4979-4985.	0.6	148
12	The genetic basis of von Willebrand disease. Blood Reviews, 2010, 24, 123-134.	2.8	145
13	Somatic Mosaicism in Hemophilia A: A Fairly Common Event. American Journal of Human Genetics, 2001, 69, 75-87.	2.6	144
14	The Molecular Basis of Hemophilia A: Genotype-Phenotype Relationships and Inhibitor Development. Seminars in Thrombosis and Hemostasis, 2003, 29, 023-030.	1.5	118
15	Precise Carrier Diagnosis in Families with Haemophilia A: Use of Conformation Sensitive Gel Electrophoresis for Mutation Screening and Polymorphism Analysis. Thrombosis and Haemostasis, 1998, 79, 723-726.	1.8	102
16	Clinical and laboratory variability in a cohort of patients diagnosed with type 1 VWD in the United States. Blood, 2016, 127, 2481-2488.	0.6	96
17	von Willebrand disease. Genetics in Medicine, 2011, 13, 365-376.	1.1	87
18	VWF propeptide and ratios between VWF, VWF propeptide, and FVIII in the characterization of type 1 von Willebrand disease. Blood, 2013, 121, 2336-2339.	0.6	86

#	Article	IF	Citations
19	HemophiliaÂB: molecular pathogenesis and mutation analysis. Journal of Thrombosis and Haemostasis, 2015, 13, 1184-1195.	1.9	86
20	Aberrant methylation of the negative regulators RASSFIA, SHP-1 and SOCS-1 in myelodysplastic syndromes and acute myeloid leukaemia. British Journal of Haematology, 2005, 129, 60-65.	1.2	83
21	Analysis of intracellular storage and regulated secretion of 3 von Willebrand diseaseâ€“causing variants of von Willebrand factor. Blood, 2003, 102, 2452-2458.	0.6	74
22	Methylation of the suppressor of cytokine signaling 3 gene (SOCS3) in myeloproliferative disorders. Haematologica, 2008, 93, 1635-1644.	1.7	74
23	Genomic structure of human FLT3 : implications for mutational analysis. British Journal of Haematology, 2001, 113, 1076-1077.	1.2	73
24	A study of Wilson disease mutations in Britain. , 1999, 14, 304-311.		70
25	Identification and characterization of a novel P2Y12 variant in a patient diagnosed with type 1 von Willebrand disease in the European MCMDM-1VWD study. Blood, 2009, 113, 4110-4113.	0.6	67
26	The International Society on Thrombosis and Haematosis von Willebrand Disease Database: An Update. Seminars in Thrombosis and Hemostasis, 2011, 37, 470-479.	1.5	67
27	Two novel type 2N von Willebrand diseaseâ€“causing mutations that result in defective factor VIII binding, multimerization, and secretion of von Willebrand factor. Blood, 2000, 95, 2000-2007.	0.6	61
28	Factor VIII gene rearrangements in patients with severe haemophilia A. Lancet, The, 1994, 343, 329-330.	6.3	60
29	A novel von Willebrand diseaseâ€“causing mutation (Arg273Trp) in the von Willebrand factor propeptide that results in defective multimerization and secretion. Blood, 2000, 96, 560-568.	0.6	58
30	Curated diseaseâ€¢causing genes for bleeding, thrombotic, and platelet disorders: Communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 2019, 17, 1253-1260.	1.9	56
31	Late Relapsing Childhood Lymphoblastic Leukemia. Blood, 1998, 92, 2334-2337.	0.6	55
32	Relationship between Factor VIII Mutation Type and Inhibitor Development in a Cohort of Previously Untreated Patients Treated with Recombinant Factor VIII (Recombinateâ„¢). Thrombosis and Haemostasis, 2000, 83, 844-848.	1.8	55
33	Specific and global coagulation assays in the diagnosis of discrepant mild hemophilia A. Haematologica, 2013, 98, 1980-1987.	1.7	48
34	A rapid method for haemophilia B mutation detection using conformation sensitive gel electrophoresis. British Journal of Haematology, 1999, 104, 915-918.	1.2	46
35	A Standard Nomenclature for von Willebrand Factor Gene Mutations and Polymorphisms. Thrombosis and Haemostasis, 2001, 85, 929-931.	1.8	46
36	Homeologous recombination between AluSx-sequences as a cause of hemophilia. Human Mutation, 2004, 24, 440-440.	1.1	42

#	Article	IF	Citations
37	HLA class II profile: a weak determinant of factor VIII inhibitor development in severe haemophilia A. UKHCDO Inhibitor Working Party. Thrombosis and Haemostasis, 1997, 77, 234-7.	1.8	42
38	Second hit mutations in the RTK/RAS signaling pathway in acute myeloid leukemia with inv(16). Haematologica, 2004, 89, 106.	1.7	42
39	Tribbles-1 and -2 are tumour suppressors, down-regulated in human acute myeloid leukaemia. Immunology Letters, 2010, 130, 115-124.	1.1	41
40	The impact of bleeding history, von Willebrand factor and PFAâ€“100^{Â®} on the diagnosis of type 1 von Willebrand disease: results from the European study MCMDMâ€1VWD. British Journal of Haematology, 2010, 151, 245-251.	1.2	41
41	BCR-ABL Transcript With an e19a2 (c3a2) Junction in Classical Chronic Myeloid Leukemia. Blood, 1997, 89, 3064-3064.	0.6	36
42	Î±IIbÎ²3 variants defined by next-generation sequencing: Predicting variants likely to cause Glanzmann thrombasthenia. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E1898-907.	3.3	36
43	Nomenclature of genetic variants in hemostasis. Journal of Thrombosis and Haemostasis, 2011, 9, 852-855.	1.9	34
44	Assessment of the F9 genotype-specific FIX inhibitor risks and characterisation of 10 novel severe F9 defects in the first molecular series of Argentinian patients with haemophilia B. Thrombosis and Haemostasis, 2013, 109, 24-33.	1.8	34
45	Endoplasmic Reticulum Retention and Prolonged Association of a von Willebrand's Disease-Causing von Willebrand Factor Variant with ERp57 and Calnexin. Biochemical and Biophysical Research Communications, 2001, 280, 448-453.	1.0	31
46	Mutational analysis of class III receptor tyrosine kinases (C-KIT, C-FMS, FLT3) in idiopathic myelofibrosis. British Journal of Haematology, 2003, 120, 464-470.	1.2	31
47	Diagnosing von Willebrand disease: genetic analysis. Hematology American Society of Hematology Education Program, 2016, 2016, 678-682.	0.9	31
48	Are aberrant BCR-ABL transcripts more common than previously thought?. British Journal of Haematology, 2000, 111, 1109-1111.	1.2	31
49	Characterisation of Type 2N von Willebrand Disease Using Phenotypic and Molecular Techniques. Thrombosis and Haemostasis, 1996, 75, 959-964.	1.8	30
50	The incidence of inhibitor development according to specific mutations - and treatment?. Blood Coagulation and Fibrinolysis, 2003, 14, S17-S21.	0.5	29
51	Gene structure, expression profiling and mutation analysis of the tumour suppressor SHIP1 in Caucasian acute myeloid leukaemia. Leukemia, 2007, 21, 2390-2393.	3.3	29
52	JAK2 V617F Mutation is uncommon in chronic myelomonocytic leukaemia. British Journal of Haematology, 2005, 130, 968-968.	1.2	28
53	Evaluation of a semiâ€automated von Willebrand factor multimer assay, the Hydragel 5 von Willebrand multimer, by two European Centers. Research and Practice in Thrombosis and Haemostasis, 2018, 2, 790-799.	1.0	27
54	Next Generation Sequencing in Newborn Screening in the United Kingdom National Health Service. International Journal of Neonatal Screening, 2019, 5, 40.	1.2	27

#	Article	IF	Citations
55	A novel von Willebrand disease-causing mutation (Arg273Trp) in the von Willebrand factor propeptide that results in defective multimerization and secretion. Blood, 2000, 96, 560-8.	0.6	27
56	Type 1 von Willebrand disease: application of emerging data to clinical practice. Haemophilia, 2008, 14, 685-696.	1.0	26
57	Genetic testing for von Willebrand disease: the case for. Journal of Thrombosis and Haemostasis, 2010, 8, 13-16.	1.9	26
58	Laboratory methods for the genetic diagnosis of bleeding disorders. International Journal of Laboratory Hematology, 1998, 20, 3-19.	0.2	25
59	Sixteen novel hemophilia A causative mutations in the first Argentinian series of severe molecular defects. Haematologica, 2007, 92, 842-845.	1.7	25
60	p.Tyr365Cys change in factor VIII: haemophilia A, but not as we know it. British Journal of Haematology, 2011, 154, 618-625.	1.2	23
61	Mutations in PTPN11 are uncommon in adult myelodysplastic syndromes and acute myeloid leukaemia. British Journal of Haematology, 2004, 124, 843-844.	1.2	22
62	The UK National External Quality Assessment Scheme (UK NEQAS) for molecular genetic testing in haemophilia. Thrombosis and Haemostasis, 2006, 96, 597-601.	1.8	20
63	Bleeding symptoms in patients diagnosed as type 3 von Willebrand disease: Results from 3WINTERSâ€IPS, an international and collaborative crossâ€sectional study. Journal of Thrombosis and Haemostasis, 2020, 18, 2145-2154.	1.9	20
64	Molecular Genetic Testing of Hemophilia A. Seminars in Thrombosis and Hemostasis, 2008, 34, 491-501.	1.5	18
65	A novel von Willebrand diseaseâ€“causing mutation (Arg273Trp) in the von Willebrand factor propeptide that results in defective multimerization and secretion. Blood, 2000, 96, 560-568.	0.6	18
66	Advances in carrier detection in haemophilia. Haemophilia, 1998, 4, 358-364.	1.0	17
67	Quality in Molecular Biology Testing for Inherited Thrombophilia Disorders. Seminars in Thrombosis and Hemostasis, 2012, 38, 600-612.	1.5	17
68	Polymorphic variation within the VWF gene contributes to the failure to detect mutations in patients historically diagnosed with type 1 von Willebrand disease from the MCMDM-1VWD cohort. Haematologica, 2010, 95, 2163-2165.	1.7	16
69	Analysis of factor VIII gene intron 1 inversion in Argentinian families with severe haemophilia A and a review of the literature. Blood Coagulation and Fibrinolysis, 2004, 15, 569-572.	0.5	16
70	Mutational analysis of the von Willebrand factor gene in type 1 von Willebrand disease using conformation sensitive gel electrophoresis: a comparison of fluorescent and manual techniques. Haematologica, 2007, 92, 550-553.	1.7	16
71	Precise carrier diagnosis in families with haemophilia A: use of conformation sensitive gel electrophoresis for mutation screening and polymorphism analysis. Thrombosis and Haemostasis, 1998, 79, 723-6.	1.8	16
72	Clonal stability in late-relapsing childhood lymphoblastic leukaemia. British Journal of Haematology, 1997, 98, 992-994.	1.2	15

#	Article	IF	Citations
73	c-FMS mutational analysis in acute myeloid leukaemia. British Journal of Haematology, 2003, 123, 749-750.	1.2	15
74	A rapid and cost effective method for analysis of dinucleotide repeat polymorphisms in the factor VIII gene. Blood Coagulation and Fibrinolysis, 1996, 7, 672-677.	0.5	14
75	Haemophilia A and von Willebrandâ€™s disease. Haemophilia, 2010, 16, 79-84.	1.0	14
76	Genomics of bleeding disorders. Haemophilia, 2014, 20, 50-53.	1.0	14
77	The common VWF single nucleotide variants c.2365A>G and c.2385T>C modify VWF biosynthesis and clearance. Blood Advances, 2018, 2, 1585-1594.	2.5	14
78	A comparison of the allelic frequencies of ten DNA polymorphisms associated with factor VIII and factor IX genes in Thai and Western European populations. Blood Coagulation and Fibrinolysis, 1994, 5, 29-36.	0.5	12
79	FLT3 internal tandem duplication mutations are rare in agnogenic myeloid metaplasia. Blood, 2002, 100, 364-364.	0.6	12
80	Genetics of type 1 von Willebrand disease. Current Opinion in Hematology, 2007, 14, 444-449.	1.2	12
81	Identification and characterisation of mutations associated with von Willebrand disease in a Turkish patient cohort. Thrombosis and Haemostasis, 2013, 110, 264-274.	1.8	12
82	Relationship between factor VIII mutation type and inhibitor development in a cohort of previously untreated patients treated with recombinant factor VIII (Recombinate). Recombinate PUP Study Group. Thrombosis and Haemostasis, 2000, 83, 844-8.	1.8	12
83	The molecular basis of von Willebrand disease: the under investigated, the unexpected and the overlooked. Haematologica, 2011, 96, 798-800.	1.7	11
84	Diagnosis and Management of von Willebrand Disease in the United Kingdom. Seminars in Thrombosis and Hemostasis, 2011, 37, 488-494.	1.5	11
85	Genotypes of European and Iranian patients with type 3 von Willebrand disease enrolled in 3WINTERS-IPS. Blood Advances, 2021, 5, 2987-3001.	2.5	11
86	Reassortants of influenza B viruses for use in vaccines: An evaluation. Archives of Virology, 1985, 83, 169-179.	0.9	10
87	Null Alleles Are not a Common Cause of Type 1 von Willebrand Disease in the British Population. Thrombosis and Haemostasis, 1999, 82, 1373-1375.	1.8	9
88	FLT3 internal tandem duplication mutations in adult acute myeloid leukaemia define a highâ€risk group. British Journal of Haematology, 2000, 111, 190-195.	1.2	9
89	Is routine molecular screening for common Î±-thalassaemia deletions necessary as part of an antenatal screening programme?. Journal of Medical Screening, 2007, 14, 60-61.	1.1	9
90	Genetics of haemostasis. Haemophilia, 2012, 18, 73-80.	1.0	9

#	Article	IF	Citations
91	Two novel type 2N von Willebrand disease-causing mutations that result in defective factor VIII binding, multimerization, and secretion of von Willebrand factor. Blood, 2000, 95, 2000-7.	0.6	9
92	A standard nomenclature for von Willebrand factor gene mutations and polymorphisms. On behalf of the ISTH SSC Subcommittee on von Willebrand factor. Thrombosis and Haemostasis, 2001, 85, 929-31.	1.8	9
93	The UK National External Quality Assessment Scheme for Heritable Bleeding Disorders. Seminars in Thrombosis and Hemostasis, 2014, 40, 261-268.	1.5	7
94	A standard nomenclature for von Willebrand factor gene mutations and polymorphisms. Best Practice and Research in Clinical Haematology, 2001, 14, 235-240.	0.7	6
95	Characterization of large in-frame von Willebrand factor deletions highlights differing pathogenic mechanisms. Blood Advances, 2020, 4, 2979-2990.	2.5	6
96	The Complete Type I VWD Cohort Of The Zimmerman Program For The Molecular and Clinical Biology Of VWD - Phenotypic Assignment, Mutation Frequency, and Bleeding Assessment. Blood, 2013, 122, 332-332.	0.6	6
97	Identification and Characterization of Novel Variations in Platelet G-Protein Coupled Receptor (GPCR) Genes in Patients Historically Diagnosed with Type 1 von Willebrand Disease. PLoS ONE, 2015, 10, e0143913.	1.1	6
98	Activating loop mutations in the PDGFR Î± and Î² genes are rare in core binding factor acute myeloid leukaemia. British Journal of Haematology, 2004, 127, 123-124.	1.2	5
99	p.P2063S: a neutral VWF variant masquerading as a mutation. Annals of Hematology, 2014, 93, 505-506.	0.8	5
100	The UK National External Quality Assessment Scheme (UK NEQAS) for molecular genetic testing in haemophilia. Thrombosis and Haemostasis, 2006, 96, 597-601.	1.8	5
101	A SECOND CASE OF Hb RENERT [Î²133(H11)Val â†' Ala]. Hemoglobin, 2001, 25, 337-340.	0.4	3
102	VWF sequence variants: a data goldmine. Blood, 2013, 122, 471-473.	0.6	3
103	Comparison of Phenotypic Assessment and Mutation Detection in the Diagnosis of Carrier State in Hemophilia: Identification of 10 Novel Mutations.. Blood, 2004, 104, 4020-4020.	0.6	3
104	Reâ€evaluation of three Israeli families initially diagnosed with type 1 von Willebrand disease in light of the ISTH update on von Willebrand factor pathophysiology and classification. Haemophilia, 2008, 14, 621-624.	1.0	2
105	When 1 plus 1 equals 3 in VWD. Blood, 2009, 114, 933-934.	0.6	2
106	Vicenza deciphered: modeling the von Willebrand disease enigma: commentary on accelerated clearance alone explains ultralarge multimers in VWD Vicenza. Journal of Thrombosis and Haemostasis, 2010, 8, 1271-1272.	1.9	2
107	Genetic analysis of bleeding disorders. Haemophilia, 2016, 22, 79-83.	1.0	2
108	Intracellular Retention, Enhanced Clearance, and Defective FVIII Binding Are Common Features of Von Willebrand Factor D'-D3 Domain Mutations in Patients with Von Willebrand Disease Type 1 From the European Mcmdm-1VWD Study. Blood, 2012, 120, 99-99.	0.6	2

#	Article	IF	Citations
109	Clustering of Bleeding Symptoms in Patients Previously Diagnosed As Type 3 Von Willebrand Disease: Results from a Large Cohort of Type 3 Von Willebrand Disease (the 3Winters-Ips Project). Blood, 2018, 132, 2465-2465.	0.6	2
110	A common splice site mutation is shared by two families with different type 2N von Willebrand disease mutations. Thrombosis and Haemostasis, 1999, 82, 1061-4.	1.8	2
111	Are aberrant BCR -ABL transcripts more common than previously thought?. British Journal of Haematology, 2000, 111, 1109-1111.	1.2	1
112	Authors' response to Dong-Zhi Li's letter: â€˜Routine molecular screening for common Â±-Thalassaemia deletions is necessary as part of an antenatal screening programmeâ€™. Journal of Medical Screening, 2008, 15, 47-47.	1.1	1
113	Another step towards understanding hemophilia A molecular pathogenesis. Journal of Thrombosis and Haemostasis, 2010, 8, 2693-2695.	1.9	1
114	von Willebrand Factor/Factor VIII Binding Is not Affected by the Arg89Gln Polymorphism in von Willebrand Factor. Thrombosis and Haemostasis, 1996, 76, 820-821.	1.8	1
115	Characterisation of type 2N von Willebrand disease using phenotypic and molecular techniques. Thrombosis and Haemostasis, 1996, 75, 959-64.	1.8	1
116	von Willebrand factor/factor VIII binding is not affected by the Arg89Gln polymorphism in von Willebrand factor. Thrombosis and Haemostasis, 1996, 76, 820-1.	1.8	1
117	Phenotypic and Genotypic Signatures of VWF Exon 18 in Eastern Saudi Patients Previously Diagnosed with Type 1 von Willebrand Disease. International Journal of General Medicine, 0, Volume 15, 5385-5394.	0.8	1
118	Characterization of type 2N von Willebrand disease using molecular and phenotypic analysis. Blood Coagulation and Fibrinolysis, 1995, 6, 178.	0.5	0
119	A novel FVIII gene inversion which causes severe haemophilia A. Blood Coagulation and Fibrinolysis, 1995, 6, 155.	0.5	0
120	Genetics for Hematologists: The Molecular Genetic Basis of Haematological Disorders. British Journal of Haematology, 2002, 117, 255-255.	1.2	0
121	In silico analysis highlights the copy number variation mechanism responsible for the historically reported <scp>VWF</scp> exon 42 deletion. Haemophilia, 2016, 22, e484-7.	1.0	0
122	Genetic and Laboratory Diagnosis. , 0, , 153-166.		0
123	Promoter Methylation of RASSFIA, SHP1 and SOCS1 Genes in Acute Myeloid Leukaemia (AML) and Myelodysplastic Syndromes (MDS).. Blood, 2004, 104, 2999-2999.	0.6	0
124	Investigation of Underlying Reasons of Factor VIII Deficiency in Haemophilia A Patients with Undetectable Mutations in the Factor VIII Gene.. Blood, 2006, 108, 1042-1042.	0.6	0
125	Investigation of the Role of Copy Number Variation In the Pathogenesis of Type 1 Von Willebrand Disease. Blood, 2010, 116, 2218-2218.	0.6	0
126	Late Relapsing Childhood Lymphoblastic Leukemia. Blood, 1998, 92, 2334-2337.	0.6	0

#	Article	IF	Citations
127	Characterization and Expression of an In-Frame Exon 33-34 Deletion Causing Type 1 VWD. Blood, 2014, 124, 1525-1525.	0.6	0
128	Identification of Novel Mutations with Molecular Modelling of Missense Mutations of Congenital Afibrinogenemia Patients in Pakistan. Blood, 2015, 126, 4664-4664.	0.6	0
129	Profile of Mutations Identified in the 3WINTERS-IPS Project on European & Iranian Patients with Previously Diagnosed Type 3 Von Willebrand Disease.. Blood, 2018, 132, 1184-1184.	0.6	0
130	Enhanced carrier and prenatal diagnosis in the Italian haemophilia B population. Blood Transfusion, 2007, 5, 117-9.	0.3	0
131	Null alleles are not a common cause of type 1 von Willebrand disease in the British population. Thrombosis and Haemostasis, 1999, 82, 1373-5.	1.8	0